Parametric response mapping of contrast-enhanced biphasic CT for evaluating tumour viability of hepatocellular carcinoma after TACE

European Radiology
Jan B HinrichsThomas Rodt

Abstract

To determine the feasibility and role of parametric response mapping (PRM) for quantitative assessment of regional contrast-enhancement patterns in hepatocellular carcinoma (HCC). Biphasic CT of 19 patients receiving repetitive conventional transarterial chemoembolisation (cTACE) for intermediate stage HCC were retrospectively analysed at baseline and follow-up at 3, 6, and 9 months. Voxel-based registration of arterial and porto-venous phases, with segmentation of the largest target lesion was performed. Frequency distribution plots of density-pairs of segmented voxels were generated. To differentiate necrotic, hypervascular and non-hypervascular tumour, and lipiodol/calcification, thresholds of 30, 100, and 300 HU were applied. Changes in density frequency plots over time were analysed and compared to response and assessment criteria (WHO, RECIST, EASL, mRECIST) and survival. PRM was feasible in all cases. Tumour volumes and hypervascular/non-hypervascular volume ratio showed significant longitudinal decrease (p < 0.05). Hypervascular volume at baseline was inversely correlated to survival (R = -0.57, p = 0.005). The only predictive parameter following cTACE to show significant survival difference was the change of the viable...Continue Reading

References

Jan 1, 1981·Cancer·A B MillerA Winkler
May 1, 2002·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Chung-Mau LoJohn Wong
Jan 24, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Josep M Llovet, Jordi Bruix
Oct 9, 2007·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·Wolfgang SchimaThomas Gruenberger
May 13, 2008·Gastroenterology·Hashem B El-SeragK Rajender Reddy
May 15, 2008·Journal of the National Cancer Institute·Josep M LlovetUNKNOWN Panel of Experts in HCC-Design Clinical Trials
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Dec 23, 2008·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·E A EisenhauerJ Verweij
Apr 21, 2009·Nature Medicine·Craig J GalbánBrian D Ross
Oct 23, 2009·Cardiovascular and Interventional Radiology·Roman KloecknerMichael B Pitton
Feb 23, 2010·Seminars in Liver Disease·Riccardo Lencioni, Josep M Llovet
Feb 26, 2011·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Rita GolfieriLuigi Bolondi
Aug 23, 2012·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Vincenzo MazzaferroCarlo Spreafico
Feb 13, 2013·Cancer Imaging : the Official Publication of the International Cancer Imaging Society·Tiffany Hennedige, Sudhakar Kundapur Venkatesh
Jul 31, 2013·RöFo : Fortschritte auf dem Gebiete der Röntgenstrahlen und der Nuklearmedizin·C NiessenP L Pereira
Feb 5, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Lei LiuGuohong Han
Feb 24, 2015·Journal of Vascular and Interventional Radiology : JVIR·Amy R DeipolyiSuvranu Ganguli
Apr 29, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jennifer J KnoxLaura A Dawson

❮ Previous
Next ❯

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.